Budipine

Budipine (brand name Parkinsan) is an antiparkinson agent marketed for the treatment of Parkinson's disease.[2][3]

Budipine

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	N04BX03 (WHO)
Identifiers
IUPAC name 1-tert-butyl-4,4-diphenylpiperidine[1]
CAS Number	57982-78-2^Y
PubChem CID	68778
ChemSpider	62021^Y
UNII	L9026OPI2Z
KEGG	D07306^Y
ChEMBL	ChEMBL334491^Y
CompTox Dashboard (EPA)	DTXSID20206709
ECHA InfoCard	100.055.494
Chemical and physical data
Formula	C21H27N
Molar mass	293.454 g·mol^−1
3D model (JSmol)	Interactive image
SMILES c1(ccccc1)C3(c2ccccc2)CCN(C(C)(C)C)CC3
InChI InChI=1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3^Y Key:QIHLUZAFSSMXHQ-UHFFFAOYSA-N^Y
(verify)

While its exact mechanism of action is not well characterized,[2] it is believed to be an NMDA receptor antagonist,[4][5] but also promoting the synthesis of dopamine.[6]

Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.[6][7]

See also

• AD-1211
• Delucemine
• Diphenidine
• Ephenidine
• Fluorolintane
• Lanicemine
• Methoxphenidine (MXP)
• MT-45
• Remacemide

References

1. Martndale: The Complete Drug Reference, 35th Ed.
2. Heinz Reichmann (October 2006). "Budipine in Parkinson's tremor". Journal of the Neurological Sciences. 248 (1–2): 53–55. doi:10.1016/j.jns.2006.05.039. PMID 16784759.
3. H. Przuntek; T. Müller (1999). Clinical efficacy of budipine in Parkinson's disease. Journal of Neural Transmission. Supplementa. 56. pp. 75–82. doi:10.1007/978-3-7091-6360-3_3. ISBN 978-3-211-83275-2. PMID 10370903.
4. Kornhuber J., Herr B., Thome J., Riederer P. (1995). "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J. Neural Transm. Suppl. 46: 127–133. PMID 8821048.CS1 maint: multiple names: authors list (link)
5. Gene C. Palmer (September 2001). "Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies". Current Drug Targets. 2 (3): 241–271. doi:10.2174/1389450013348335. PMID 11554551.
6. Przuntek H, Bittkau S, Bliesath H, et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263. Archived from the original on 2011-08-10. Retrieved 2008-08-04.
7. Jenny C.E. Owen; Peter S. Whitton (October 2006). "Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats". Brain Research. 1117 (1): 206–212. doi:10.1016/j.brainres.2006.07.039. PMID 16996043.